Deal Alert: Manas AI’s $26M Trigger
Manas AI locks in $26M seed extension & new CTO. Adjust your pipeline. Pitch your AI drug discovery platform and close fast.
Published on
Do not index
Do not index
🚀 Battle Card: Manas AI
Quick trigger:
👤 Decision Maker in the News
- Ujjwal Singh, Co-Founder and Chief Technology Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/manasai/)
💡 Why It Matters
- The extension amplifies runway for foundational model development, signaling deep investor confidence in AI-native drug R&D. → Source This is a Manas AI sales trigger.
🎯 Core Pain Point
- Long, costly drug discovery cycles
- Lack of scalable AI infrastructure for lead optimization
💰 What to Pitch
- Primary: AI-powered drug discovery platform → accelerated lead identification
- Expansion: Neuro-symbolic model integration consulting → enhanced predictive accuracy
🗺️ Quick Context
- HQ: New York, NY
- Employees: ≈ 40
- Rev: ≈ $2M
🤼 Competitive Intel
Which other vendors you’ll probably face to win Manas AI’s business.
- Recursion Pharmaceuticals — AI-driven phenomics platform
- Unique edge: Extensive biological image dataset
- Evaluated by Head of R&D for high-throughput screening
- Atomwise — Structure-based AI discovery
- Unique edge: Deep CNN for binding affinity prediction
- Evaluated by CTO for model accuracy
- Insilico Medicine — Generative chemistry AI
- Unique edge: End-to-end target-to-lead generation
- Evaluated by VP of Drug Discovery for speed
- BenevolentAI — Knowledge graph drug discovery
- Unique edge: Integrated biomedical literature analysis
- Evaluated by CSO for hypothesis generation
- Exscientia — AI-driven small molecule design
- Unique edge: Rapid candidate design with clinical validation
- Evaluated by CFO for ROI and time savings
✅ Do-Now Checklist
Connect with all decision makers on LinkedIn (links above)
Generate email + DM with the Copy-My-Prompt block (Step 7), referencing the Manas AI sales trigger, and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑≈ TBD❑
OFFER_BRIEF = ❑AI-powered drug discovery platform❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Ujjwal
COMPANY = Manas AI
DEPT = Eng
SIZE = ≈ 10
BOTTLENECK = long, costly drug discovery cycle
EVENT = $26M seed extension
DETAIL = closing $26M Seed Extension
PAIN = long, costly drug discovery cycle
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250923943644&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 40
REV_EST = ≈ $2M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈ 10-person Eng
Ujjwal—noticed your Eng team is ≈ 10.
That’s when long, costly drug discovery cycle slows growth.
We helped ≈ TBD fix this with AI-powered drug discovery platform.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about closing $26M Seed Extension — long, costly drug discovery cycle.
AI-powered drug discovery platform. ≈ TBD.
Quick chat?